Table I.
Autoantibody and antibody-mediated immune phenomena in patients treated with ustekinumab
| Age | Sex | Ustekinumab indication | Prior autoimmune-mediated disease | New clinical manifestation after ustekinumab | Ustekinumab duration at time of onset of new disease (mo) | Study |
|---|---|---|---|---|---|---|
| 43 | F | Psoriasis | Prior SLE | Lupus nephritis vasculopathy | 20 | Current study |
| 46 | M | Psoriasis Psoriatic arthritis |
None | Probable lupus Nephritis (membranoproliferative glomerulonephritis with immune complex) Vasculitis |
24 | Current study |
| 25 | F | Psoriasis | Prior SLE | Lupus nephritis | 3 – Ustekinumab continued | Current study and Tselios et al,1 2017 |
| 62 63 58 |
M M M |
Psoriasis Psoriatic arthritis Psoriasis |
None Not reported Not reported |
Bullous pemphigoid | 10 18 2 |
Le Guern et al,9 2015 Nakayama et al,10 2015 Onsun et al,11 2017 |
| 31 | F | Psoriasis | Not reported | Linear IgA bullous dermatosis | 2 | Becker 201612 |